|Anti-hCD20-hIgA1||Unit size||Cat. code||Docs||Price|
Human CD20 (Rituximab) antibody - Human IgA1
Monoclonal human IgA1 antibody against human CD20
Anti-hCD20-hIgA1 features the constant region of the human IgA1 isotype and the variable region of rituximab.
Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.
Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.
Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.
Anti-hCD20-hIgA1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.
Back to the top
Clonality: Monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgA1, kappaBack to the top
- 100 µg purified anti-hCD20-hIgA1 antibody, provided azide-free and lyophilized.
Product is shipped at room temperature.
Store lyophilized antibody at -20°C.
Lyophilized product is stable for 1 year.Back to the top